No Data
On January 2, Guosheng Holdings (02273.HK) spent 1.986 million HKD to repurchase 0.06 million shares.
On January 2, Gulonghui announced that Guishengtang (02273.HK) spent 1.986 million HKD to repurchase 0.06 million shares.
[Brokerage Focus] Huaan maintains a "Buy" rating on Gu Shengtang (02273), being bullish on the company's influence and future development in the field of Traditional Chinese Medicine diagnosis and treatment.
Jinwu Financial News | Huaan Securities research pointed out that Gushengtang (02273) has formed a Global Strategy cooperation with ShanDong University of Traditional Chinese Medicine. In the future, both parties will fully leverage their respective advantages to engage in deep cooperation in various fields, jointly promoting the development of Traditional Chinese Medicine to new heights. The report indicated that on September 23 last year, the National Medical Insurance Administration, in collaboration with the Jiangsu Province Medical Insurance Bureau, conducted a comprehensive inspection of over 100 designated Medical Institutions and pharmacies in the entire Wuxi area. On October 8, the National Medical Insurance Administration reported on the flying inspection situation at Wuxi Hongqiao Hospital. The management of medical insurance is becoming stricter, with varying degrees of rectification, penalties, and business closures for non-compliant stores, leading to a belief in compliance.
Gushengtang Holdings Limited's (HKG:2273) Market Cap Touched HK$8.1b Last Week, Benefiting Both Retail Investors Who Own 48% as Well as Institutions
Hong Kong stocks move | Gushengtang (02273) rose over 5% in the afternoon. The sound regulation is Bullish for legal and compliant enterprises' Operation. The company is expected to actively promote the growth of customer traffic and average transaction v
Guishengtang (02273) rose more than 5% in the afternoon. As of the time of this report, it is up 4.95%, trading at HKD 32.85, with a transaction value of HKD 32.8332 million.
[Brokerage Focus] China Merchants maintains a "Strong Buy" rating on Guishengtang (02273), expecting the company's ability to attract high-quality doctors to continue improving.
Jinwu Financial News | China Merchants released a Research Report stating that Gu Shengtang (02273) signed a Global Strategy cooperation agreement with Jiangyin Traditional Chinese Medicine Hospital in July this year, and established the Gu Shengtang Jiangyin Expert Committee to continuously promote the construction of the medical alliance. Taking this cooperation as an opportunity, Gu Shengtang and Jiangyin Traditional Chinese Medicine Hospital are working together on major specialist construction, Traditional Chinese Medicine technology exchanges, talent training, and scientific research innovation, further promoting the orderly flow of high-quality resources from top-tier hospitals through market mechanisms. The bank pointed out that the national medical insurance special inspection is stringent, and the company is legally compliant in terms of medical insurance, while non-compliant stores in the Industry are gradually being eliminated, which is expected to further optimize the competitive landscape.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Investors Give Zhejiang Crystal-Optech Co., Ltd (SZSE:002273) Shares A 27% Hiding
